Gilead

Latest articles

1h
FOX Business
Gilead Slaps Mega-Price on Its Newly Approved CARclass of cancer killers to get the regulatory nod and Yescarta's $373,000 price
FOX Business / Posted an hour ago
class of cancer killers to get the regulatory nod and Yescarta's $373,000 price tag suggests it could meaningfully offset Gilead Sciences' declining hepatitis C drug revenue next year. Cell therapy arrives Yescarta is a chimeric antigen receptor... Read more
105 related articles
1h
FOX Business
Gilead Slaps Mega-Price on Its Newly Approved CARclass of cancer killers to get the regulatory nod and Yescarta's $373,000 price
FOX Business / Posted an hour ago
class of cancer killers to get the regulatory nod and Yescarta's $373,000 price tag suggests it could meaningfully offset Gilead Sciences' declining hepatitis C drug revenue next year. Cell therapy arrives Yescarta is a chimeric antigen receptor... Read more
105 related articles
3h
The Youngstown Vindicator
Youngstown news, Obituaries, Tributes, LOUVENIA MATTIE THACKER, Youngstown, OhioYOUNGSTOWN – Funeral services will be held at 10 a.m. on Saturday, Oct. 21, 201
The Youngstown Vindicator / Posted 3 hours ago
YOUNGSTOWN – Funeral services will be held at 10 a.m. on Saturday, Oct. 21, 2017, at the Mt. Gilead Baptist Church, for Louvenia Mattie Thacker, 88, who departed this life on Wednesday, Oct. 11, 2017, quietly and peacefully at home. Mrs. Thacker was... Read more
5h
San Francisco Chronicle
FDA approves second gene-altering treatment for cancerrights to commercialize the results. Largely on the strength of the new drug a
San Francisco Chronicle / Posted 5 hours ago
rights to commercialize the results. Largely on the strength of the new drug and related research, Foster City drug giant Gilead purchased Kite in August, for $11.9 billion. “Today marks another milestone in the development of a whole new... Read more
105 related articles
6h
TribLIVE
Last-minute rebound lifts S&P 500, Dow edge to new highsand other health care companies. Envision Healthcare led the sector, vaulting
TribLIVE / Posted 6 hours ago
and other health care companies. Envision Healthcare led the sector, vaulting $4.43, or 10.9 percent, to $45.08. Gilead Sciences rose $1.58, or 2 percent, to $81.59. A subsidiary of the drugmaker received approval this week to sell a new... Read more
274 related articles
6h
Boston Globe
Last-minute gain lifts S&P 500, Dow to new highsup shares in drug manufacturers and other health care companies. Envision Heal
Boston Globe / Posted 6 hours ago
up shares in drug manufacturers and other health care companies. Envision Healthcare led the sector, rising 10.9 percent. Gilead Sciences rose 2 percent. A subsidiary of the drug maker received approval this week to sell a new treatment for a form... Read more
274 related articles
7h
Business Insider
A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer2015, helping run clinical trials for Kite Pharma, the company that developed Y
Business Insider / Posted 7 hours ago
2015, helping run clinical trials for Kite Pharma, the company that developed Yescarta that has since been acquired by Gilead Sciences. Novartis, the company that makes Kymriah, is also working to get the drug approved in an aggressive form of... Read more
105 related articles
8h
Stamford Advocate
A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer (GILD)2015, helping run clinical trials for Kite Pharma, the company that developed Y
Stamford Advocate / Posted 8 hours ago
2015, helping run clinical trials for Kite Pharma, the company that developed Yescarta that has since been acquired by Gilead Sciences. Novartis, the company that makes Kymriah, is also working to get the drug approved in an aggressive form of... Read more
105 related articles
8h
Connecticut Post
A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer (GILD)2015, helping run clinical trials for Kite Pharma, the company that developed Y
Connecticut Post / Posted 8 hours ago
2015, helping run clinical trials for Kite Pharma, the company that developed Yescarta that has since been acquired by Gilead Sciences. Novartis, the company that makes Kymriah, is also working to get the drug approved in an aggressive form of... Read more
105 related articles
9h
KECI Missoula
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasdecades. He called the approval a "milestone." The new drug is made by Califor
KECI Missoula / Posted 9 hours ago
decades. He called the approval a "milestone." The new drug is made by California-based Kite, a subsidiary of drug giant Gilead Sciences that develops chimeric antigen receptor and T-cell receptor (CAR-T) cell therapies. These new treatments use... Read more
105 related articles
9h
WCYB 5 Tri-Cities
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasdecades. He called the approval a "milestone." The new drug is made by Califor
WCYB 5 Tri-Cities / Posted 9 hours ago
decades. He called the approval a "milestone." The new drug is made by California-based Kite, a subsidiary of drug giant Gilead Sciences that develops chimeric antigen receptor and T-cell receptor (CAR-T) cell therapies. These new treatments use... Read more
105 related articles
9h
KRDO Colorado Springs
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasdecades. He called the approval a "milestone." The new drug is made by Califor
KRDO Colorado Springs / Posted 9 hours ago
decades. He called the approval a "milestone." The new drug is made by California-based Kite, a subsidiary of drug giant Gilead Sciences that develops chimeric antigen receptor and T-cell receptor (CAR-T) cell therapies. These new treatments use... Read more
105 related articles
10h
ABC 7 El Paso
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasdecades. He called the approval a "milestone." The new drug is made by Califor
ABC 7 El Paso / Posted 10 hours ago
decades. He called the approval a "milestone." The new drug is made by California-based Kite, a subsidiary of drug giant Gilead Sciences that develops chimeric antigen receptor and T-cell receptor (CAR-T) cell therapies. These new treatments use... Read more
105 related articles
10h
News 8000
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasdecades. He called the approval a "milestone." The new drug is made by Califor
News 8000 / Posted 10 hours ago
decades. He called the approval a "milestone." The new drug is made by California-based Kite, a subsidiary of drug giant Gilead Sciences that develops chimeric antigen receptor and T-cell receptor (CAR-T) cell therapies. These new treatments use... Read more
105 related articles
10h
The Scientist
FDA Approves Second CAR T-Cell Therapyof the treatment began at the National Cancer Institute, then moved to Kite in
The Scientist / Posted 10 hours ago
of the treatment began at the National Cancer Institute, then moved to Kite in 2012, The New York Times reports. Gilead acquired Kite in August. The FDA granted the approval to Kite, which will continue to produce the drug. That process,... Read more
105 related articles
11h
FOX 2 News St. Louis
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasdecades. He called the approval a “milestone.” The new drug is made by Califor
FOX 2 News St. Louis / Posted 11 hours ago
decades. He called the approval a “milestone.” The new drug is made by California-based Kite, a subsidiary of drug giant Gilead Sciences that develops chimeric antigen receptor and T-cell receptor (CAR-T) cell therapies. These new treatments use... Read more
105 related articles
12h
The Hindu
U.S. approves second gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
The Hindu / Posted 12 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
12h
Daily Mail
US regulators approve 2nd gene therapy for blood cancerFDA Commissioner Dr. Scott Gottlieb said in a statement. Yescarta will cost $3
Daily Mail / Posted 12 hours ago
FDA Commissioner Dr. Scott Gottlieb said in a statement. Yescarta will cost $373,000 per patient, according to drug-maker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
13h
CBS News
Gene therapy for blood cancer wins FDA approvalScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
CBS News / Posted 13 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
13h
Chicago Tribune
University of Chicago to offer newly approved gene therapy for adults with cancerPharma, will be marketed as Yescarta and will carry a price, before insurance,
Chicago Tribune / Posted 13 hours ago
Pharma, will be marketed as Yescarta and will carry a price, before insurance, of $373,000. Kite was recently purchased by Gilead Sciences. “We conducted extensive research with commercial and government payers, as well as targeted cancer centers,... Read more
105 related articles
13h
Mashable
Game-changing gene therapy to treat blood cancer approved by the FDApatients while rekindling a global conversation about the escalating cost of ne
Mashable / Posted 13 hours ago
patients while rekindling a global conversation about the escalating cost of new therapies. The treatment, made by Gilead Sciences, is made by extracting patients’ white blood cells and re-engineering them to home in on tumors. Called a... Read more
105 related articles
13h
WSFA 12 Montgomery
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
WSFA 12 Montgomery / Posted 13 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
14h
TribLIVE
FDA approves gene therapy to treat adult lymphomain fighting non-Hodgkin lymphoma. The treatment, called Yescarta, will cost $3
TribLIVE / Posted 14 hours ago
in fighting non-Hodgkin lymphoma. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. The price is below that of the first drug in this new class - Novartis AG's $475,000 Kymriah. The Novartis... Read more
105 related articles
15h
NBC 2 Fort Myers
FDA approves cutting-edge cancer treatment 'for patients without hope'Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost
NBC 2 Fort Myers / Posted 15 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. Read the full story on WCVB... Read more
105 related articles
15h
NBC 29 Charlottesville
FDA approves cutting-edge cancer treatment 'for patients without hope'Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost
NBC 29 Charlottesville / Posted 15 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. Read the full story on WCVB... Read more
105 related articles
15h
ABC 7 Gulfshore News
FDA approves cutting-edge cancer treatment 'for patients without hope'Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost
ABC 7 Gulfshore News / Posted 15 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. Read the full story on WCVB... Read more
105 related articles
15h
Reuters
FDA approves Gilead cancer gene therapy; price set at $373,000(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of l
Reuters / Posted 15 hours ago
(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc’s (GILD.O) Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The... Read more
105 related articles
16h
Zero Hedge
October 19on Feb. 1, capping a 16-year run at the card company as it grapples with a new
Zero Hedge / Posted 16 hours ago
on Feb. 1, capping a 16-year run at the card company as it grapples with a new wave of competition. on.wsj.com/2ytobjO - Gilead Sciences' $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite's flagship cell-therapy... Read more
16h
Channel NewsAsia
US FDA approves Gilead cancer gene therapy; price set at US$373,000REUTERS: U.S. regulators approved on Wednesday a new therapy for a type of lymp
Channel NewsAsia / Posted 16 hours ago
REUTERS: U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and... Read more
105 related articles
16h
Reuters
U.S. FDA approves Gilead cancer gene therapy; price set at $373,000(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of l
Reuters / Posted 16 hours ago
(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc’s Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and... Read more
105 related articles
17h
The Jewish Press
Kite Pharma, Launched by Israeli Scientists, Gets FDA Approval for Lymphoma Treatment | 29 Tishri 5778 – October 19, 2017in the emerging field of cell therapy founded by Israeli scientist Dr. Arieh Be
The Jewish Press / Posted 17 hours ago
in the emerging field of cell therapy founded by Israeli scientist Dr. Arieh Belldegrun, was acquired in late August by Gilead Sciences for $11.9 billion. Yescarta was developed by Prof. Zelig Ashchar of the Department of Immunology at the... Read more
105 related articles
20h
WECT 6 Wilmington
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
WECT 6 Wilmington / Posted 20 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
22h
KWWL Iowa
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
KWWL Iowa / Posted 22 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
23h
WBOC Salisbury
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
WBOC Salisbury / Posted 23 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
23h
WFMJ Youngstown
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
WFMJ Youngstown / Posted 23 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
23h
WLOX-TV Biloxi
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
WLOX-TV Biloxi / Posted 23 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
23h
WIS News 10 Columbia
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
WIS News 10 Columbia / Posted 23 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
23h
ABC Montana
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
ABC Montana / Posted 23 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
23h
Jefferson City News Tribune
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
Jefferson City News Tribune / Posted 23 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
23h
Boston Globe
FDA backs gene therapy for cancerreceived rights to commercialize the results. Largely on the strength of the n
Boston Globe / Posted 23 hours ago
received rights to commercialize the results. Largely on the strength of the new drug and related research, the drug giant Gilead purchased Kite in August, for $11.9 billion. “Today marks another milestone in the development of a whole new... Read more
105 related articles
23h
Lake Placid News
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
Lake Placid News / Posted 23 hours ago
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
1d
FOX Business
FDA approves Gilead cancer gene therapy; price set at $373,000U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, whi
FOX Business / Posted yesterday
U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug... Read more
105 related articles
1d
FOX Business
FDA approves Gilead cancer gene therapy; price set at $373,000U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, whi
FOX Business / Posted yesterday
U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. Continue Reading... Read more
105 related articles
1d
WAVE 3 Louisville
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
WAVE 3 Louisville / Posted yesterday
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
1d
Your Hometown Lima Stations
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
Your Hometown Lima Stations / Posted yesterday
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
1d
FOX 8 New Orleans
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
FOX 8 New Orleans / Posted yesterday
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
1d
NBC 2 Fort Myers
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
NBC 2 Fort Myers / Posted yesterday
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
1d
KHQ Spokane
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
KHQ Spokane / Posted yesterday
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
1d
KFDA-TV Amarillo
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
KFDA-TV Amarillo / Posted yesterday
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
1d
KCBD-TV Lubbock
US regulators approve 2nd gene therapy for blood cancerScott Gottlieb said in a statement. The treatment, called Yescarta, will cost
KCBD-TV Lubbock / Posted yesterday
Scott Gottlieb said in a statement. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead Sciences. Kite became a subsidiary of Foster City, California-based Gilead this month. CAR-T treatment uses gene... Read more
105 related articles
More

In this news